Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

Early diagnosis underpins NHS cancer strategy

Paul Midgley, Oli Hudson and Sarah Shield, of Wilmington Healthcare, explore how the NHS is tackling cancer in line with the Long-term Plan

Wilmington Healthcare

- PMLiVE

Launch Excellence 2020

In this special pack, we provide a comprehensive outlook of launch excellence. We cover topics ranging from gathering effective insights, to understanding the current landscape, and the importance of pre-launch...

Blue Latitude Health

- PMLiVE

Ashfield appoints new UK head of patient solutions

Stephanie Hill strengthens the commercial team at leading healthcare network

- PMLiVE

OPEN Health reflections on the World Orphan Drug Congress in Barcelona

Having just returned from a very busy but hugely enjoyable few days at congress, I wanted to share our views on the event and key themes that our healthcare communications...

OPEN Health

- PMLiVE

Vertex reveals promising data from first CRISPR-treated patients

Investigational gene therapy has potentially curative effect

- PMLiVE

J&J’s new Darzalex formulation OK’d for use in Europe

Extends use of multiple myeloma therapy even further

- PMLiVE

Myovant preps US filing for relugolix in prostate cancer

Takeda-partnered drug had 97% response rate in advanced prostate cancer

- PMLiVE

The Medicines Company surges on rumours of Novartis takeover

Buyers interested in company as it prepares to file CV drug inclisiran

The Unhappiness Project

How come I can’t find anyone who is ‘happy’ with healthcare?

Bayer symbol

Bayer, Merck’s high-risk heart failure drug comes good in phase 3

Significantly reduced the risk of hospitalisation or cardiovascular death

- PMLiVE

Karuna’s shares spike on schizophrenia drug data

Value leaps to more than $1bn following mid-stage trial results

Novartis day

Novartis changes focus in Shanghai from early research to drug development

Swiss pharma switches focus of $1bn R&D institute

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links